Calithera Biosciences to Present at Two Healthcare Conferences in September
August 31 2016 - 9:00AM
Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage
pharmaceutical company focused on discovering and developing novel
small molecule drugs directed against tumor metabolism and tumor
immunology targets for the treatment of cancer, today announced its
participation at two upcoming healthcare investor conferences in
September. The presentations will be webcast live, and available
for replay for up to 30 days at www.calithera.com in the Investor
Relations section.
- Wells Fargo Securities Healthcare Conference.
Susan M. Molineaux, Ph.D, the company’s Founder, President
and Chief Executive Officer, will present in Boston on Thursday,
September 8, at 1:45 p.m. Eastern Time.
- BioCentury 23rd Annual NewsMakers in the Biotech
Industry Conference. Susan M. Molineaux, Ph.D, the
company’s Founder, President and Chief Executive Officer, will
present in New York on Friday, September 9, at 3:00 p.m. Eastern
Time.
About Calithera Biosciences
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical
company focused on discovering and developing novel small molecule
drugs directed against tumor metabolism and tumor immunology
targets for the treatment of cancer. Calithera’s lead product
candidate, CB-839, is a potent, selective, reversible and orally
bioavailable inhibitor of glutaminase. CB-839 takes advantage
of the pronounced dependency many cancers have on the nutrient
glutamine for growth and survival. It is currently being
evaluated in Phase 1/2 clinical trials in combination with
standard of care agents. CB-1158 is a first-in-class
immuno-oncology metabolic checkpoint inhibitor targeting arginase,
a critical immunosuppressive enzyme responsible for T‑cell
suppression by myeloid-derived suppressor cells. Arginase
depletes arginine, a nutrient that is critical for the activation,
growth and survival of the body’s cancer-fighting immune cells,
known as cytotoxic T-cells. Calithera is headquartered in
South San Francisco, California. For more information about
Calithera, please visit www.calithera.com.
Forward Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Words such as "may," "will," "expect," "anticipate,"
"estimate," "intend," "poised" and similar expressions (as well as
other words or expressions referencing future events, conditions,
or circumstances) are intended to identify forward-looking
statements. These statements include those related to the
safety, tolerability and efficacy of CB-839, enrollment of the
combination expansion cohorts of CB-839 and the presentation of
additional combination data in 2016. Because such statements
are subject to risks and uncertainties, actual results may differ
materially from those expressed or implied by such forward-looking
statements. The potential product candidates that Calithera
develops may not progress through clinical development or receive
required regulatory approvals within expected timelines or at all.
In addition, clinical trials may not confirm any safety, potency or
other product characteristics described or assumed in this press
release. Such product candidates may not be beneficial to
patients or successfully commercialized. The failure to meet
expectations with respect to any of the foregoing matters may have
a negative effect on Calithera's stock price. Additional
information concerning these and other risk factors affecting
Calithera's business can be found in Calithera's most recent
Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission, and other periodic filings with the Securities
and Exchange Commission at www.sec.gov. These forward-looking
statements are not guarantees of future performance and speak only
as of the date hereof, and, except as required by law, Calithera
disclaims any obligation to update these forward-looking statements
to reflect future events or circumstances.
Contact:
Jennifer McNealey
ir@Calithera.com
650-870-1071
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Apr 2023 to Apr 2024